Skip to Content

Statin Use Tied to Better COVID-19 Survival

MONDAY, March 15, 2021 -- Prehospitalization statin use is associated with lower inpatient mortality among patients hospitalized with COVID-19, according to research published online Feb. 26 in Nature Communications.

Aakriti Gupta, M.D., from New York-Presbyterian Hospital and the Columbia University Irving Medical Center in New York City, and colleagues analyzed data from 2,626 patients admitted with COVID-19 from Feb. 1 through May 12, 2020, with follow-up ending June 11, 2020. Using data from electronic medical records, the authors assessed previous statin use.

The researchers found that 36.2 percent of participants were antecedent statin users. In a propensity score-matched cohort of 1,296 patients (648 statin users and 648 nonusers), statin use was associated with significantly lower odds of the primary end point of in-hospital mortality within 30 days (odds ratio, 0.47), with the primary end point occurring in 14.8 and 26.5 percent of patients receiving statins and those not receiving statins, respectively. The secondary endpoint of invasive mechanical ventilation at 30 days occurred in 18.6 and 21.9 percent of patients receiving statins and those not receiving statins, respectively (odds ratio, 0.76).

"If their beneficial effect bears out in randomized clinical trials, statins could potentially prove to be a low-cost and effective therapeutic strategy for COVID-19," a coauthor said in a statement.

Abstract/Full Text

© 2021 HealthDay. All rights reserved.

Read this next

COVID-19 Infection May Up Mortality in Surgical Patients

TUESDAY, April 13, 2021 -- COVID-19 infection is an independent risk factor for surgical mortality, according to a research letter published online April 12 in JAMA Network...

WHO Urges Halt to Sale of Live Wild Animals at Food Markets

TUESDAY, April 13, 2021 -- Countries should suspend the sale of live wild animals at food markets because they are a leading source of emerging infectious diseases such as...

FDA, CDC Call for Pause in J&J COVID-19 Vaccine After Six People Develop Clots

TUESDAY, April 13, 2021 -- After six people who received the Johnson & Johnson one-dose COVID-19 vaccine developed a type of rare and severe blood clot, the U.S. Food and Drug...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.